Drug intelligence / Profile preview

donepezil + ginkgo biloba extract

Development stage: Unknown
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of donepezil, an acetylcholinesterase inhibitor, and ginkgo biloba extract (typically EGb 761), a herbal medicine with antioxidant and potential anti-amyloid properties. This combination has been studied for the treatment of Alzheimer's disease, particularly in patients with neuropsychiatric features. Clinical evidence suggests potential synergistic effects on cognitive function and biomarkers of disease progression, with some studies indicating better tolerability compared to donepezil monotherapy.

Other names: donepezil + EGb 761

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on donepezil + ginkgo biloba extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + ginkgo biloba extract.

Explore the full profile